• Monday - Thursday: 9.00 am - 6.00 pm

Studies – Currently Recruiting


A Trial of the Safety and Therapeutic Effects of ILYX-002 Versus Vehicle Control for Treatment of Dry-Eye Disease in Patients with Autoimmune Disease.

A Multicenter, Randomized, Controlled, Double-Masked, Phase 2 Trial of the Safety and Therapeutic Effects of ILYX-002 Versus Vehicle Control for Treatment of Dry-Eye Disease in Patients with Autoimmune Disease

The purpose of this study is to assess the safety and therapeutic effects (how well a treatment works) of ILYX-002 for the treatment of Dry-Eye Disease. This study will be conducted in patients with Autoimmune Disease, aged 18-85 years old.

This study will compare ILYX-002 with vehicle/placebo. A vehicle is a medication with no active ingredients. It looks similar to the real thing, but it is not. One group of participants will receive a low-dose of ILYX-002, one group will receive high dose of ILYX-002 and the other group will receive the vehicle/placebo. The effects seen in participants receiving the study drug will be compared to the effects seen in participants who receive vehicle/placebo. Each group will involve approximately 50 participants, with 150 participants to be enrolled in total.

Australia and New Zealand Clinical Trial Registry link:

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386135&isReview=true